Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of hengagliflozin in Chinese patients with type 2 diabetes mellitus
ChiCTR2400088679Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of henagliflozin in type 2 diabetes mellitus (T2DM), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: Glycosylated hemoglobin (HbA1c). Planned start Aug 2024; status: not yet recruiting.
02
Drugs
henagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2400088679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088679.